Dr. Moazzam Shahzad, MD

Dr. Shahzad practices at H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida.

Dr. Shahzad's NPI, 1932653375, was assigned on August 13, 2016. Dr. Shahzad graduated from Allama Iqbal Medical College in 2012. Dr. Shahzad holds Florida license ME154349.

Dr. Shahzad's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD, at 10901 McKinley Dr, Tampa, FL 33612.

Dr. Shahzad's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida. Dr. Shahzad is also affiliated with Moffitt Cancer Hospital. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Shahzad to 5 more medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shahzad practices, 4 sites in all. Vendor and product names are available with a free account.

Hospitalist is Dr. Shahzad's primary specialty in the NPI Registry, under taxonomy code 208M00000X. Dr. Shahzad is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Shahzad's licenses on file in 2 states: Florida and West Virginia.

CMS data shows 28 Medicare services from Dr. Shahzad across 1 procedure code in 2024, for 35 Medicare patients. Medicare paid $3,766 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 35 Medicare patients who saw Dr. Shahzad in 2024. The largest group is 75 to 84, with 19 patients. 75% of them have high blood pressure, and 66% have high cholesterol. Their average risk score is 1.81, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shahzad's median patient age at 69, with 29% women.

In 2020, Dr. Shahzad wrote 32 Medicare Part D claims. Every claim was for a generic drug. They cover 2 drugs, with $327 in total drug cost. In 2019, CMS named 27 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 82 out of 100 for Dr. Shahzad for performance year 2024, reported as part of a group. Dr. Shahzad accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Shahzad as offering telehealth.

Dmand AI links 42 papers to Dr. Shahzad, published from 2019 to 2025. 2024 was the busiest year, with 13. The most frequent topics are Hematopoietic Stem Cell Transplantation, Transplantation, Homologous and Graft vs Host Disease. Dr. Shahzad has published most often in Leuk Lymphoma. Dr. Shahzad's most frequent co-authors are Muhammad Umair Mushtaq, MD, Nausheen Ahmed, MD and Sibgha Gull Chaudhary, MD.

CMS Open Payments shows 51 general payments to Dr. Shahzad from 17 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 100% of the total. Janssen Pharmaceuticals, Inc paid the most, $589.

Dr. Shahzad graduated from Allama Iqbal Medical College in 2012. Dr. Shahzad is a member of ACP, AMA, American Society for Transplantation and Cellular Therapy, ASCO and ASH.

Dr. Shahzad is in network with 3 carriers, including CareSource, KY State Medicaid and WV State Medicaid. Medicaid plans come from the most carriers, 3. Check the plan with the practice before a visit.